Overview
Thymosin Alpha-1 is one of the most studied immunomodulatory peptides in modern medicine. Approved in over thirty countries for hepatitis and immune deficiency. Used in veterinary practice for cats with feline leukemia virus and feline immunodeficiency virus. Prescribed off-label for immune-mediated disease in dogs.
Immune balance. Not immune stimulation. That is the difference that matters.
Mechanism of action
- 01Activates Toll-like receptor 2 and 9 signaling on plasmacytoid dendritic cells.
- 02Expands and matures naive T-cell populations in the thymus and peripheral tissues.
- 03Shifts cytokine profile toward Th1 immunity. Interferon gamma up. IL-10 balanced.
- 04Enhances natural killer cell activity against virus-infected cells.
- 05Restores immune competence in immunosuppressed states without triggering autoimmunity.
Molecular data
Species
Dog
Immune-mediated hemolytic anemia adjunct. Chronic viral respiratory disease. Cancer supportive care alongside chemotherapy. Preclinical mammalian immune biology maps directly to canine T-cell function.
Cat
The strongest species case. Published case series in FeLV and FIV positive cats show improved clinical outcomes. Chronic upper respiratory disease in shelter medicine. Chronic gingivostomatitis adjunct.
Prescribing indications
- ImmunePrimary useFeLV positive cats with clinical illness. FIV positive cats with recurrent infection.
- ImmuneSupportedImmune-mediated hemolytic anemia adjunct. Chronic viral respiratory disease.
- OncologyEmergingCancer supportive care alongside chemotherapy under specialist supervision.
Dosing and administration
Starting, maintenance, and loading doses are calculated in the platform for the patient’s weight band, at the vial strength our compounding partner dispenses, and drawn to U-100 syringe units for the client’s dosing card. Any override is logged with your initials.
See the worked dose exampleScreening and safety
Screen first
Standard screening
Follow up
Infection frequency, clinical signs, and bloodwork your case calls for. Measure at baseline and recheck at 4 to 6 weeks with the same measure.
Excellent tolerability in over three decades of human clinical use. No significant drug interactions documented. No cortisol elevation. No dependency. Contraindicated in transplant patients on immunosuppressive therapy.
Common pairings
- Thymosin Alpha-1 + InterferonCompatibleCoordinated dosing recommended.
Veterinary questions
Is Thymosin Alpha-1 FDA approved for animals?+
No. Compounded for individual patients under FDA GFI 256. Not FDA approved for animals or humans in the United States.
Can I use it alongside interferon?+
Yes. The mechanisms complement one another. Coordinated dosing recommended.
Does it work for FIP?+
Emerging. Case reports exist. Not first-line.
Is it safe long term?+
Human clinical data supports long-term use. Veterinary long-term data is limited.
Can I combine with other injectable peptides?+
Yes. Common combinations include BPC-157 for gut recovery in FeLV cats with chronic enteropathy.
References
Related
This monograph describes a compounded veterinary medication available by prescription only through a licensed veterinarian inside an active veterinarian-client-patient relationship. Not FDA-approved for animal or human use. Compounded on a patient-specific basis under FDA Guidance for Industry #256. For educational use by licensed veterinarians. Not intended for consumer self-prescribing.